Archives

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Presenter: Anna FleischerSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:15 PM–2:30 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

Abstract Number: 258 – Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Presenter: Joao Tadeu Damian Souto Filho, MD, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad TherapiesDate & Time: Saturday, December 7, 2024 3:15 PM–3:30 PMLocation: Pacific...

Abstract Number: 252 – Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Presenter: Palak BajajSession: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma OutcomesDate & Time: Saturday, December 7, 2024 3:15 PM–3:30 PMLocation: San Diego Ballroom AB (Marriott Marquis...

Abstract Number: 247 – Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Presenter: Ciara Louise Freeman, PhD, MSc, FRCPC, MRCPSession: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma OutcomesDate & Time: Saturday, December 7, 2024 2:00 PM–2:15 PMLocation: San...

Abstract Number: 79 – Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Presenter: Joshua Gustine, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?Date & Time: Saturday, December 7, 2024 9:30 AM–9:45 AMLocation: Pacific...

« Older Entries

Next Entries »

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Abstract Number: 258 – Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Abstract Number: 252 – Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Abstract Number: 247 – Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Abstract Number: 79 – Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Recent Posts

Recent Comments

Categories

Meta